What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof



I

wherein

R is C_{1-4} alkyl, CF_3 or hydroxymethyl;

R^1 and R^2 are each independently hydrogen, C_{1-4} alkyl, halogen or morpholin-4-yl;

R^4 is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C_{1-4}alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R^5 is hydrogen or fluoro; or R^4 and R^5 taken together are –CH=CH-CH=CH- or $-CH_2CH_2O-$; and

R^3, R^6 and R^7 are each independently selected from hydrogen or fluoro.

2. The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



Ic

wherein

R is methyl or hydroxymethyl;

R^1 and R^2 are each independently hydrogen, C_{1-4} alkyl, halogen or morpholin-4-yl;

R^4 is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C_{1-4}alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R^5 is hydrogen or fluoro; or R^4 and R^5 taken together are –CH=CH-CH=CH- or $-CH_2CH_2O-$; and

R^3, R^6 and R^7 are each independently selected from hydrogen or fluoro.

3. The compound of claim 1 selected from the group consisting of:

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide ;

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;
2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;
2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;
2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyll}-amide;
2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-amide;
2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;
2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;
(S)-2-phenyl-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;
(S)-2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;
(S)-2-phenyl-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; and
(S)-2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;
or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.

5. A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof, which comprises

administering to said mammal a therapeutically effective amount of the compound of claim 1.

6. The method of claims 5 wherein said disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders.

7. The method of claim 6 wherein said disorder is migraine.

8. The method of claim 6 wherein said disorder is neuropathic pain.